TQB2858
As of the edition of 20 October 2026, TQB2858 is a drug known only by a code name: stopped in 2023; acts on CD274 and TGFB1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2023
- Kind
- Code name only
- Registered trials
- 7, 3 stopped early
- Disease areas
- Cancer; Digestive system; Ear, nose and throat; Hormones; Mouth and teeth; Pregnancy and women's health
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
3 company-target rows on route A because of this drug.
Companies on route A for this drug
In the product3 company-target rows are on route A because of TQB2858.
See the 3 company-target rows on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 3 | 0 | 0 | 1 |
| Phase 2 | 4 | 0 | 0 | 2 |
| All trials | 7 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Chia Tai Tianqing Pharmaceutical | Lead sponsor of trials | 2021 to now |
| Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical | Lead sponsor of trials | 2022 to now |